| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 55.20M | 53.00M | 64.00M | 40.20M | 24.46M |
| Gross Profit | 32.20M | 36.10M | 47.00M | 24.30M | 16.31M |
| EBITDA | 5.90M | -64.10M | 49.40M | 33.80M | 52.93M |
| Net Income | -100.30M | -88.80M | 6.90M | 20.20M | 49.61M |
Balance Sheet | |||||
| Total Assets | 1.18B | 1.27B | 1.44B | 1.72B | 693.60M |
| Cash, Cash Equivalents and Short-Term Investments | 52.50M | 40.50M | 19.90M | 7.60M | 2.69M |
| Total Debt | 376.60M | 448.30M | 481.10M | 703.70M | 22.29M |
| Total Liabilities | 409.10M | 478.30M | 521.50M | 766.20M | 39.51M |
| Stockholders Equity | 761.10M | 788.00M | 912.60M | 951.20M | 654.09M |
Cash Flow | |||||
| Free Cash Flow | 22.70M | 18.30M | 6.40M | 888.90M | -473.92M |
| Operating Cash Flow | 22.70M | 18.30M | 6.40M | 11.10M | 19.96M |
| Investing Cash Flow | 105.00M | 83.90M | 41.50M | -961.90M | -522.47M |
| Financing Cash Flow | -80.70M | -81.60M | -35.60M | 944.10M | 501.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$690.72M | 4.31 | 24.81% | 3.97% | 11.19% | 34.96% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
64 Neutral | AU$381.59M | 2.70 | 7.93% | 7.46% | -3.97% | 1057.09% | |
56 Neutral | AU$85.73M | -5.93 | -2.01% | 3.95% | -5.21% | -14350.00% | |
54 Neutral | AU$357.61M | -3.71 | -10.44% | 11.21% | -16.67% | -1419.67% | |
53 Neutral | AU$609.28M | 2.79 | -1.91% | 8.63% | -4.50% | 88.28% | |
49 Neutral | AU$58.36M | -4.82 | -23.55% | 15.14% | -68.24% | 42.03% |
HealthCo Healthcare & Wellness REIT has disclosed a change in director Kelly O’Dwyer’s holdings following her acquisition of additional units in the trust. O’Dwyer bought 23,328 fully paid ordinary units at $0.72 per unit, lifting her direct holding to 149,221 units while her indirect interest through the Jonkel Family Trust remains at 38,626 units.
The purchase represents the first tranche of a two-part acquisition under HealthCo’s FY26 voluntary non-executive director unit acquisition arrangement, implemented via the manager’s existing product disclosure framework. The transaction, which was not conducted during a closed trading period, signals ongoing alignment between the director’s interests and those of unitholders through increased equity participation.
The most recent analyst rating on (AU:HCW) stock is a Hold with a A$0.64 price target. To see the full list of analyst forecasts on HealthCo Healthcare & Wellness REIT stock, see the AU:HCW Stock Forecast page.
HealthCo Healthcare and Wellness REIT has disclosed a change in the securities held by non-executive director Joseph Carrozzi AM, in line with ASX listing rule requirements. The notice details that Carrozzi, who previously held 435,612 fully paid ordinary units, acquired an additional 22,674 units on 4 March 2026 at $0.72 per unit, taking his total holding to 458,286 units.
The acquisition represents the first tranche of a two-part purchase under HealthCo’s FY26 voluntary non-executive director unit acquisition arrangement, implemented under a product disclosure framework established in 2021. The transaction was not conducted during a closed trading period, underscoring routine governance processes rather than an opportunistic trade, and signals continued alignment of board interests with those of unitholders through increased equity participation.
The most recent analyst rating on (AU:HCW) stock is a Hold with a A$0.64 price target. To see the full list of analyst forecasts on HealthCo Healthcare & Wellness REIT stock, see the AU:HCW Stock Forecast page.
HealthCo Healthcare and Wellness REIT has disclosed a change in the securities held by director Natalie Jane Meyenn, reflecting increased alignment between board interests and unitholders. Meyenn acquired 27,537 fully paid ordinary units at $0.72 per unit on 4 March 2026, lifting her direct holding to 188,542 units.
The purchase forms the first tranche of two under the FY26 voluntary non-executive director unit acquisition arrangement, implemented via a product disclosure statement dated August 2021. The transaction, which did not involve any disposal of units or trading during a closed period, underscores ongoing director participation in the REIT’s equity-based arrangements.
The most recent analyst rating on (AU:HCW) stock is a Hold with a A$0.64 price target. To see the full list of analyst forecasts on HealthCo Healthcare & Wellness REIT stock, see the AU:HCW Stock Forecast page.
HMC Capital has announced the timetable for releasing half-year financial results to 31 December 2025 for its listed vehicles, including HealthCo Healthcare & Wellness REIT, with a series of result announcements and accompanying investor briefings and webcasts scheduled across February 2026. The structured program of conference calls and webcasts, supported by pre-registration and dedicated investor presentations, signals an organised investor relations push aimed at providing detailed disclosure and engagement with shareholders across HMC Capital’s platform, including the healthcare and wellness real estate portfolio.
The most recent analyst rating on (AU:HCW) stock is a Hold with a A$0.80 price target. To see the full list of analyst forecasts on HealthCo Healthcare & Wellness REIT stock, see the AU:HCW Stock Forecast page.
HealthCo Healthcare & Wellness REIT announced updates on its capital management and tenant agreements, emphasizing efforts to maintain financial stability amid ongoing transitional challenges with Healthscope. Healthscope remains compliant with leasing obligations, while HCW proactively prepares to finalize lease agreements with alternative tenants for its hospital assets should the Healthscope sale process not meet terms. Additionally, HCW has implemented strategic asset sales generating $76.8 million in proceeds to ensure adequate liquidity and balance sheet strength. As a further measure to preserve liquidity, HCW will temporarily suspend quarterly distributions until the Healthscope situation is resolved, reflecting their operational focus and financial prudence.
The most recent analyst rating on (AU:HCW) stock is a Hold with a A$0.85 price target. To see the full list of analyst forecasts on HealthCo Healthcare & Wellness REIT stock, see the AU:HCW Stock Forecast page.